###begin article-title 0
###xml 47 70 47 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Francisella tularensis </italic>
###xml 47 69 <span type="species:ncbi:263">Francisella tularensis</span>
A novel receptor - ligand pathway for entry of Francisella tularensis in monocyte-like THP-1 cells: interaction between surface nucleolin and bacterial elongation factor Tu
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 0 22 0 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Francisella tularensis</italic>
###xml 466 480 466 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 0 22 <span type="species:ncbi:263">Francisella tularensis</span>
###xml 88 93 <span type="species:ncbi:9606">human</span>
###xml 466 479 <span type="species:ncbi:263">F. tularensis</span>
Francisella tularensis, the causative agent of tularemia, is one of the most infectious human bacterial pathogens. It is phagocytosed by immune cells, such as monocytes and macrophages. The precise mechanisms that initiate bacterial uptake have not yet been elucidated. Participation of C3, CR3, class A scavenger receptors and mannose receptor in bacterial uptake have been already reported. However, contribution of an additional, as-yet-unidentified receptor for F. tularensis internalization has been suggested.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 69 92 69 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Francisella tularensis </italic>
###xml 69 91 <span type="species:ncbi:263">Francisella tularensis</span>
###xml 160 165 <span type="species:ncbi:9606">human</span>
###xml 590 596 <span type="species:ncbi:10090">murine</span>
We show here that cell-surface expressed nucleolin is a receptor for Francisella tularensis Live Vaccine Strain (LVS) and promotes LVS binding and infection of human monocyte-like THP-1 cells. The HB-19 pseudopeptide that binds specifically carboxy-terminal RGG domain of nucleolin inhibits LVS binding and infection of monocyte-like THP-1 cells. In a pull-down assay, elongation factor Tu (EF-Tu), a GTP-binding protein involved in protein translation, usually found in cytoplasm, was recovered among LVS bacterial membrane proteins bound on RGG domain of nucleolin. A specific polyclonal murine antibody was raised against recombinant LVS EF-Tu. By fluorescence and electron microscopy experiments, we found that a fraction of EF-Tu could be detected at the bacterial surface. Anti-EF-Tu antibodies reduced LVS binding to monocyte-like THP-1 cells and impaired infection, even in absence of complement and complement receptors. Interaction between EF-Tu and nucleolin was illustrated by two different pull-down assays using recombinant EF-Tu proteins and either RGG domain of nucleolin or cell solubilized nucleolin.
###end p 5
###begin title 6
Discussion
###end title 6
###begin p 7
###xml 141 164 141 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Francisella tularensis </italic>
###xml 380 394 380 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 398 408 398 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tularensis</italic>
###xml 703 717 703 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 141 163 <span type="species:ncbi:263">Francisella tularensis</span>
###xml 363 368 <span type="species:ncbi:9606">human</span>
###xml 380 393 <span type="species:ncbi:263">F. tularensis</span>
###xml 703 716 <span type="species:ncbi:263">F. tularensis</span>
Altogether, our results demonstrate that the interaction between surface nucleolin and its bacterial ligand EF-Tu plays an important role in Francisella tularensis adhesion and entry process and may therefore facilitate invasion of host tissues. Since phagosomal escape and intra-cytosolic multiplication of LVS in infected monocytes are very similar to those of human pathogenic F. tularensis ssp tularensis, the mechanism of entry into monocyte-like THP-1 cells, involving interaction between EF-Tu and nucleolin, might be similar in the two subspecies. Thus, the use of either nucleolin-specific pseudopeptide HB-19 or recombinant EF-Tu could provide attractive therapeutic approaches for modulating F. tularensis infection.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 0 23 0 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Francisella tularensis </italic>
###xml 183 184 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 187 201 187 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 307 308 307 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 309 310 309 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 473 487 473 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 652 653 652 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 692 706 692 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 717 728 717 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tularensis </italic>
###xml 748 762 748 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 773 784 773 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">holarctica </italic>
###xml 801 815 801 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 873 874 873 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 903 917 903 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 924 938 924 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 942 954 942 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mediasiatica</italic>
###xml 960 974 960 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 978 986 978 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">novicida</italic>
###xml 1117 1131 1117 1131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 1301 1315 1301 1315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 1523 1524 1523 1524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1525 1526 1525 1526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 0 22 <span type="species:ncbi:263">Francisella tularensis</span>
###xml 148 155 <span type="species:ncbi:9986">rabbits</span>
###xml 187 200 <span type="species:ncbi:263">F. tularensis</span>
###xml 236 241 <span type="species:ncbi:9606">human</span>
###xml 299 305 <span type="species:ncbi:9606">humans</span>
###xml 313 319 <span type="species:ncbi:9606">Humans</span>
###xml 473 486 <span type="species:ncbi:263">F. tularensis</span>
###xml 672 677 <span type="species:ncbi:9606">human</span>
###xml 692 705 <span type="species:ncbi:263">F. tularensis</span>
###xml 748 761 <span type="species:ncbi:263">F. tularensis</span>
###xml 801 814 <span type="species:ncbi:263">F. tularensis</span>
###xml 903 916 <span type="species:ncbi:263">F. tularensis</span>
###xml 924 937 <span type="species:ncbi:263">F. tularensis</span>
###xml 960 973 <span type="species:ncbi:263">F. tularensis</span>
###xml 1117 1130 <span type="species:ncbi:263">F. tularensis</span>
###xml 1301 1314 <span type="species:ncbi:263">F. tularensis</span>
Francisella tularensis is a small non-motile Gram-negative bacterium that causes the zoonotic disease tularemia in large number of animals, such as rabbits, hares, and small rodents [1]. F. tularensis is also one of the most infectious human bacterial pathogens as ten bacteria can cause disease in humans [1,2]. Humans acquire infection by direct contact with sick animals, inhalation, ingestion of contaminated water or food, or by bites from ticks, mosquitoes or flies. F. tularensis has significant potential as an agent of bio-terrorism due to its infectivity and capacity to infect in form of aerosols and its ability to cause illness and death [1]. The two primary human pathogens are F. tularensis subspecies tularensis (type A strain) and F. tularensis subspecies holarctica (type B strain). F. tularensis live vaccine strain (LVS) is an attenuated type B strain [3]. Other subspecies (ssp) of F. tularensis exist: F. tularensis ssp mediasiatica, and F. tularensis ssp novicida. The four subspecies differ in terms of their pathogenicity and geographic origin, but are phylogenetically very closely related. F. tularensis is a highly virulent facultative intracellular bacterium, replicating intracellularly and disseminating within host mononuclear phagocytes. After entry into macrophages, F. tularensis initially resides in the phagosome, whose maturation is then arrested. After 2 hours of infection, the phagosome membrane is disrupted and the bacterium replicates freely in the cytoplasm of the macrophages [3,4].
###end p 9
###begin p 10
###xml 61 75 61 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 239 240 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 281 282 281 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 430 444 430 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 480 481 480 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 61 74 <span type="species:ncbi:263">F. tularensis</span>
###xml 430 443 <span type="species:ncbi:263">F. tularensis</span>
While several molecular aspects of the intracellular life of F. tularensis after entry have been elucidated, the exact mechanisms that mediate uptake of this highly infectious bacterium are still not fully understood. Participation of C3 [5], CR3 [6], class A scavenger receptors [7] and mannose receptor [8] in bacterial uptake have been already reported. However, contribution of an additional, as-yet-unidentified receptor for F. tularensis internalization has been suggested [8].
###end p 10
###begin p 11
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 681 683 681 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 737 751 737 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 802 803 802 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 804 806 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 859 860 859 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 900 902 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1000 1008 1000 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 1017 1019 1017 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1020 1022 1020 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 324 327 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 737 750 <span type="species:ncbi:263">F. tularensis</span>
###xml 1000 1015 <span type="species:ncbi:83334">E. coli O157:H7</span>
In the present work, we evaluated whether nucleolin could serve as a cell surface receptor for LVS and mediate its binding and subsequent internalization. Indeed, nucleolin has been shown to be localized not only in the nucleus [9], but also on the cell surface and to mediate internalization of specific ligands, including HIV particles [10,11]. In response to binding of a ligand to surface nucleolin, ligand-nucleolin complexes become internalized, by an active process, therefore allowing intracellular import of the ligand. Nucleolin, expressed at the cell surface in a high molecular weight protein complex, is in close association with the intracellular actin cytoskeleton [12]. Participation of actin microfilaments in uptake of F. tularensis was supported by its inhibition by cytochalasin B [5,13]. Nucleolin is also involved in cell proliferation [9] and in activation of CD21 on B cells [14]. Of particular interest, nucleolin has been recently described as a receptor for the adhesin of E. coli O157:H7 [15,16].
###end p 11
###begin p 12
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 636 650 636 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 56 61 <span type="species:ncbi:9606">human</span>
###xml 181 186 <span type="species:ncbi:9606">human</span>
###xml 446 451 <span type="species:ncbi:9606">human</span>
###xml 636 649 <span type="species:ncbi:263">F. tularensis</span>
We herein demonstrate that surface nucleolin present on human monocyte-like THP-1 cells is a functional receptor for LVS. Moreover, we demonstrate that the LVS bacterial ligand for human nucleolin is elongation factor Tu (EF-Tu). We also provide evidence that EF-Tu, a GTP-binding protein usually found in cytosol [17], is present in the LVS membranes and exposed on bacterial surface. Finally, we show that nucleolin expressed on the surface of human monocyte-like THP-1 cells interacts, through its C-terminal RGG domain, with the bacterial surface-exposed EF-Tu protein. This nucleolin - EF-Tu interaction plays an important role in F. tularensis LVS adhesion and entry process and may therefore facilitate invasion of host tissue.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 38 43 <span type="species:ncbi:9606">human</span>
Human cells, bacteria, antibodies and human serum
###end title 14
###begin p 15
###xml 45 49 45 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 163 165 146 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 235 249 218 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 311 313 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 518 525 495 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gro-gfp</italic>
###xml 550 552 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 706 708 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 846 848 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1381 1383 1358 1360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 125 129 <span type="species:ncbi:9913">calf</span>
###xml 235 248 <span type="species:ncbi:263">F. tularensis</span>
###xml 594 599 <span type="species:ncbi:10090">mouse</span>
###xml 659 665 <span type="species:ncbi:9986">rabbit</span>
###xml 1079 1084 <span type="species:ncbi:9606">human</span>
###xml 1139 1143 <span type="species:ncbi:9925">goat</span>
###xml 1149 1155 <span type="species:ncbi:9986">rabbit</span>
###xml 1157 1160 <span type="species:ncbi:9986">GAR</span>
###xml 1165 1169 <span type="species:ncbi:9925">goat</span>
###xml 1175 1180 <span type="species:ncbi:10090">mouse</span>
###xml 1182 1185 <span type="species:ncbi:10090">GAM</span>
###xml 1303 1308 <span type="species:ncbi:9606">Human</span>
The human monocyte-like cell line THP-1 (ATCC(R) Number: TIB-202trade mark) was grown in suspension in RPMI containing fetal calf serum (FCS) at 37degreesC in a CO2 incubator. Cell viability was measured by Trypan Blue exclusion test. F. tularensis Live Vaccine Strain, LVS, was kindly supplied by A. Sjostedt [18] and grown either in Schaedler broth containing vitamin K3 or on chocolate agar plates containing polyvitex (Biomerieux) at 37degreesC. LVS-GFP was obtained by transformation of LVS bacteria with pFNLTP6 gro-gfp, provided by Dr. Zahrt [19]. Antibodies (Abs) used were: polyclonal mouse anti-EF-Tu prepared in our laboratory, as described below; rabbit anti-IglA, kindly provided by Dr. Nano [20], anti-LVS (Becton Dickinson), anti-nucleolin (Abcam), anti-GST (Oncogene); monoclonal antibodies (MAbs) were anti-nucleolin (clone D3) [21], anti-glyceraldehyde phosphate dehydrogenase (GAPDH) (Santa Cruz Biotechnology) as an isotype-matched negative control for cell surface nucleolin and anti-CD11/CD18 (anti-CR3 receptors) (Abcam), which specifically recognizes the human CD11/18 activation epitope. Secondary antibodies were goat anti-rabbit (GAR) or goat anti-mouse (GAM) conjugated to HRP (Dako) for immunoblotting experiments or with Alexa Fluor cytochromes for microscopy experiments. Human serum AB (PAA) was handled in a manner to preserve complement activity [22]. Heat-inactivated (H.I.) serum was obtained by incubating serum for 30 min at 56degreesC.
###end p 15
###begin title 16
Peptide constructs
###end title 16
###begin p 17
###xml 31 32 31 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 590 592 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 915 917 915 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 329 334 <span type="species:ncbi:9606">human</span>
The synthesis of the 5 [Lys (CH2N)Pro-Arg]-template-assembled synthetic peptide referred to as HB-19 and the nine-D-arginine peptide construct, referred to as 9Arg, synthesized using Fmoc-protected D-Arg residue was as described previously [11,23]. The p63 peptide was synthesized according to the last 63 amino acid residues of human nucleolin (KGEGGFGGRGGGRGGFGGRGGGRGGRGGFGGRGRGGFGGRGGFRGGRGGGGDHKPQGKKTKFE) [24]. The synthetic F3 peptide is a tumor-homing peptide corresponding to the 34 amino acid fragment (AKVKDEPQRRSARLSAKPAPPKPEPKPKKAPAKK) of a high mobility group protein, HMG2N [25]. For the biotin-labeled p63 peptide, the biotin moiety was introduced during peptide assembly as an Fmoc Lys-biotin derivative at the N-terminus of the peptide. All peptides were obtained at a high purity (95%), and their integrity was controlled by matrix-associated laser desorption ionization-time-of-flight analysis [11].
###end p 17
###begin title 18
Preparation of subcellular fractions of LVS
###end title 18
###begin p 19
After 24 h of culture in broth, LVS bacteria were collected by centrifugation and either directly lysed in BPER buffer (Novagen) or suspended in 50 mM Tris/HCl pH 8.0. Suspended bacteria were then disintegrated in a Fast-Prep FP120 Cell Disrupter (ThermoSavant) with Fast-Prep beads using 4 repeated cycles of 30 sec at a 6.5 speed. After 10 min on ice, undisrupted microbes were eliminated by centrifugation for 5 min at 2,800 x g. Supernatant was then centrifuged for 60 min at 105,000 x g in a Beckmann Optima Max ultracentrifuge, at 4degreesC. The pellet, which contained the bacterial membranes, was washed twice in TNE (50 mM Tris, 150 mM NaCl, 1 mM EDTA, pH 8.0) by centrifugation and then solubilized for 45 min at 4degreesC in TNE containing 1% NP40 and 1% Triton X100. A further centrifugation at 12,000 x g for 20 min at 4degreesC separated the soluble membrane proteins present in the supernatant from membrane-associated proteins present in the pellet. Protein concentration of different fractions was determined by the BCA assay (Pierce).
###end p 19
###begin title 20
###xml 60 66 <span type="species:ncbi:10090">murine</span>
Preparation of EF-Tu recombinant proteins and generation of murine polyclonal antibodies
###end title 20
###begin p 21
###xml 161 167 160 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAATTC</italic>
###xml 234 240 233 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GTCGAC</italic>
###xml 572 575 571 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 578 581 577 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sal</italic>
###xml 625 633 620 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 753 755 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 625 632 <span type="species:ncbi:562">E. coli</span>
###xml 961 965 <span type="species:ncbi:10090">mice</span>
###xml 1008 1012 <span type="species:ncbi:10090">mice</span>
LVS chromosomal DNA was purified with Turbogen kit (Invitrogen). PCR reactions were performed in Bio-Rad I Thermal Cycler with 100 pmoles/mul of 5' primer 5'-CCGGAATTCATGGCTAAAGAAAAATTTGAGCGTTC-3' (nt 3141 to 3156) and 3' primer 5'CGAGTCGACTTACTCGATAATTTTAGCTACAACACCAGCACC-3' (nt 3246 to 3261). The EF-Tu amplicon of 1.1 kbp was purified on agarose gel, cloned in pCR2-TOPO1 vector (Invitrogen) and sequenced in Institut Cochin (Genomic Sequencing Department). Once its sequence confirmed, EF-Tu was subcloned in pGEX-4T1 (Amersham Biosciences) or pET28a+ (Novagen) into EcoRI-SalI sites, in DH5alpha. After transforming in E. coli strain BL21or BL21DE3, respectively, GST-fusion proteins and His-fusion proteins were produced as previously described [26] and purified either on glutathione-Sepharose 4B beads (Amersham Biosciences) or on Ni-column (Novagen), as described by manufacturers. His-fusion EF-Tu protein was used as immunogen for immunizing Balb/c mice. Non-immune serum (NIS) was obtained from mice injected only with Freund adjuvant.
###end p 21
###begin title 22
Pull-down assays
###end title 22
###begin p 23
###xml 278 280 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 219 224 <span type="species:ncbi:9606">human</span>
Pull-down assays were performed either with GST recombinant proteins or with biotin-avidin beads. For GST recombinant proteins, 5 mug of GST or GST-EF-Tu bound on glutathione-Sepharose beads were incubated with 500 mug human membrane proteins, obtained as previously described [14] by solubilizing THP-1 cell membranes with 1% NP40 in TNE, containing protease inhibitors (Roche Diagnostics). Biotin-avidin beads were used to characterize bacteria proteins bound on RGG p63 carboxy-terminal domain of nucleolin. For that purpose, 500 mug of LVS membrane proteins were incubated for 2 h at 8degreesC with different concentrations of the biotinylated p63 peptide. The complex formed between bacteria membrane proteins and biotinylated p63 peptide was isolated by purification using 100 mul avidin-agarose (ImmunoPure Immobilized Avidin, Pierce), after incubation for 2 h at 8degreesC. Specificity of the binding with the p63 domain was determined by preincubation of 500 mug of bacteria membrane proteins with unlabeled p63 peptide for 2 h at 8degreesC, before further incubation with the biotinylated p63 peptide for 2 h at 8degreesC. After extensive washes of the different samples, purified proteins were denatured by heating at 95degreesC for 10 min in sample buffer containing SDS and analyzed by SDS-PAGE and immunoblotting assays.
###end p 23
###begin title 24
Immunoblotting assays
###end title 24
###begin p 25
###xml 36 41 <span type="species:ncbi:9606">human</span>
Recombinant proteins, proteins from human cells or present in the different subcellular fractions of LVS, and proteins recovered from pull-down assays were submitted to SDS-PAGE. Separated proteins were electrotransferred on nitrocellulose membranes (Schleicher & Schuell), using a semi-dry Transblot apparatus (Bio-Rad). Membranes were incubated in Phosphate-buffered saline (PBS) containing 5% powdered milk and then with the indicated Abs. After washing in PBS/0.05% Tween-20 (PBS-T), HRP-linked secondary Abs were added. Nitrocellulose sheets were washed and binding of second Abs was detected using the ECL Plus kit (Amersham).
###end p 25
###begin title 26
###xml 13 18 <span type="species:ncbi:9606">human</span>
Infection of human cells
###end title 26
###begin p 27
###xml 356 358 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 548 550 535 537 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 1432 1434 1405 1407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 1584 1585 1557 1558 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 98 103 <span type="species:ncbi:9606">human</span>
###xml 147 152 <span type="species:ncbi:9606">Human</span>
###xml 1320 1325 <span type="species:ncbi:9606">human</span>
Thirty minutes before infection, LVS bacteria were suspended at 37degreesC in RPMI containing 10% human serum AB, except when otherwise indicated. Human monocyte-like THP-1 cells were washed in RPMI, suspended in RPMI containing 5% FCS (RPMI-FCS) and infected with LVS for 30 min at 37degreesC, without centrifugation to promote bacteria-cell interaction [27] at a Multiplicity of Infection (MOI) of 100:1 (bacteria/cell). Cells were then washed with RPMI containing 10 mug/ml gentamicin to remove extracellular bacteria, then suspended at 0.7 x 106 per ml in RPMI-FCS with gentamicin. This point was referred to as time zero (T = 0). Cells were further incubated statically for indicated times at 37degreesC. At indicated times, 100 mul THP-1 cells were lysed for 15 min in distilled water. Then, serial dilutions were performed in 0.15 M NaCl and the number of intracellular bacteria present in cells was determined by plating 100 mul on chocolate agar plates. When indicated, THP-1 cells were pretreated before infection for 2 h at 37degreesC with anti-CR3 Mab, the different peptides described above or with cytochalasin D (Sigma), an actin polymerization inhibitor. In some experiments, THP-1 cells were also pre-incubated with recombinant His-EF-Tu protein. This recombinant protein was tested for its toxicity on human cells, which was found to be negative (data not shown). Adherent THP-1 cells or blood MDM plated at 2 x 105 per ml were infected as described above for THP-1 cells in suspension, except that number of intracellular bacteria was quantified after adding 1 ml H2O to each well before plating serial dilutions.
###end p 27
###begin title 28
Fluorescence and Confocal experiments
###end title 28
###begin p 29
###xml 875 877 851 853 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 879 882 855 858 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 913 915 889 891 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 1376 1377 1352 1353 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 2069 2070 2045 2046 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 2576 2578 2552 2554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 23 28 <span type="species:ncbi:9606">human</span>
###xml 995 999 <span type="species:ncbi:9925">goat</span>
###xml 1221 1224 <span type="species:ncbi:10090">GAM</span>
###xml 1256 1259 <span type="species:ncbi:9986">GAR</span>
###xml 1986 1989 <span type="species:ncbi:10090">GAM</span>
Binding of bacteria on human cells was analyzed by either fluorescence or confocal microscopy, at the Cell Imaging Facility (Faculte de Medecine Necker Enfants-Malades). For fluorescence microscopy, THP-1 cells were incubated either with RPMI, the different peptides or recombinant His-EF-Tu for 2 h at 37degreesC. They were then infected for 30 min at 37degreesC with LVS-GFP (MOI of 100:1), which had been pre-incubated either with RPMI, NIS or anti-EF-Tu for 30 min at 37degreesC. Cells were then washed in RPMI without gentamicin and fixed with 4% para-formaldehyde (PFA), as described below. Cells were visualized with a fluorescence microscope (Zeiss Axioplan 2) using Qimaging Digital Camera with Q Capture Pro Fluorescence analysis software. For experiments by confocal microscopy, THP-1 cells infected or not with LVS, for 30 min at 37degreesC, were washed in PBS/Ca2+Mg2+ (Gibco) and suspended at 3 x 106 cells/ml. Cells were then incubated for 30 min at room temperature (RT) with 5% goat serum in PBS, to block non-specific binding sites, then for 45 min at RT with first Abs, at indicated dilutions. After washing, cells were incubated for 45 min at RT with second Abs diluted 1/100 (Alexa Fluor 488-labeled GAM and/or Alexa Fluor 546-labeled GAR) in the dark. After washing, cells were fixed with PFA for 15 min at RT and incubated for 10 min at RT with 50 mM NH4Cl to quench residual aldehydes. After centrifugation, the cell pellet was suspended in Mowiol and mounted on glass coverslips. Cells were visualized at the appropriate wavelengths under a Zeiss LSM 5 Pascal confocal microscope with argon (458/488 nm) and helium neon (543 nm) lasers with LSM analysis software. We present the photographs of cells with typical morphology and staining. For quantification by confocal microscopy, THP-1 cells were infected as described above except they were infected with LVS-GFP and then incubated with anti-nucleolin MAb, diluted 1/1000, followed by Alexa Fluor 568-labeled GAM. After fixation of cells with PFA for 15 min at RT and incubation with 50 mM NH4Cl, DAPI was added for 5 min in PBS containing 5% gelatin, before washing with PBS. Cell pellet, mounted on glass coverslip in Mowiol, was visualized with a Leica TCS SP5 confocal microscope with diode (405 nm), argon (458/488 nm), DPSS (561 nm) and helium neon (633 nm) lasers and LASAF program. Co-localization of LVS-GFP with nucleolin was measured on more than 500 cells using the "Co-localization" module of Imaris 5.0.2. software, which analyzes stacks of confocal sections, as previously described [28].
###end p 29
###begin p 30
###xml 81 83 81 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9 </sup>
###xml 136 141 <span type="species:ncbi:9606">human</span>
For direct labeling of LVS bacteria with different antibodies, a pellet of 2 x 109 LVS was processed as described above for labeling of human cells.
###end p 30
###begin title 31
Immunoelectron microscopy (IEM)
###end title 31
###begin p 32
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
LVS bacteria grown on plates were harvested, suspended in PBS and centrifuged at 12,000 x g for 30 sec to form loose pellets. Supernatant was removed and 2% PFA-0.1% glutaraldehyde in 0.1 M Millonig's phosphate buffer (MPB) was added to each pellet for 2 h. After rinsing three times with MPB, the pellets were then processed for negative-contrast IEM (nc-IEM) as previously described [29], except binding of the first antibodies diluted 1/200 was detected with a 1/30 dilution of protein A labeled with 10-nm gold spheres (Aurion, The Netherlands). The specimens were examined at 80 kV with a JEM-100CXII electron microscope (JEOL).
###end p 32
###begin title 33
FACS analysis
###end title 33
###begin p 34
###xml 310 311 310 311 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
THP-1 cells uninfected or infected by LVS, as described above, were incubated with different antibodies for 45 min at RT. After washing, THP-1 cells were incubated with Alexa Fluor 488-labeled second antibodies in dark place, for 45 min at RT. After washing, THP-1 cells were fixed with PFA and incubated in NH4Cl. Cells were then centrifuged and processed for analysis by FACS scan flow cytometer (Becton Dickinson). For each sample, 10,000 viable cells were gated following size (forward scatter, FSC) and granularity side scatter (SSC) and analyzed with Cell Questtrade mark Software (Becton Dickinson).
###end p 34
###begin title 35
Preparation of C3bi-coated erythrocytes (EC3bi) and their binding on THP-1 cells
###end title 35
###begin p 36
###xml 253 255 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 0 5 <span type="species:ncbi:9940">Sheep</span>
###xml 643 648 <span type="species:ncbi:9940">sheep</span>
Sheep erythocytes coated with IgM (EA) were kindly provided, by Dr. V. Fremeaux-Bacchi (Hopital Europeen Georges Pompidou, Paris). EC3bi were prepared by incubating EA in 10% C5-deficient serum (Sigma) for 60 min at 37degreesC, as previously described [30]. EC3bi were incubated with THP-1 cells for 60 min at RT and percentage of cells forming rosettes was determined by counting 100-200 cells in a microscope hemacytometer chamber. Prior to incubation with EC3bi, THP-1 cells were incubated either with RPMI, 10 muM HB-19 or 9R peptides or 20 mug anti-CR3 Mab for 2 h at 37degreesC. A rosette was defined as a cell with two or more adherent sheep erythrocytes.
###end p 36
###begin title 37
Statistical analyses
###end title 37
###begin p 38
Binding data were expressed as the mean +/- SD. Student's t test was used to determine the statistical differences between the various experimental and control groups. A p value of < 0.01 was considered to be statistically significant.
###end p 38
###begin title 39
Results
###end title 39
###begin title 40
Nucleolin expressed on monocyte-like THP-1 cells cell surface is down-regulated by LVS infection
###end title 40
###begin p 41
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 319 322 319 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A1</xref>
###xml 344 347 344 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A2</xref>
###xml 421 423 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 659 662 659 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A3</xref>
###xml 902 904 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 987 989 987 989 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 999 1001 997 999 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1049 1052 1047 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B1</xref>
###xml 1063 1065 1061 1063 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1 </sup>
###xml 1077 1079 1073 1075 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1 </sup>
###xml 1122 1125 1118 1121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B2</xref>
###xml 166 171 <span type="species:ncbi:9606">human</span>
We first verified the presence of nucleolin at the surface of THP-1 cells by fluorescence microscopy analysis using polyclonal and monoclonal antibodies specific for human nucleolin [12,21] (Fig 1A). When cells were first incubated with specific and secondary antibodies before treatment with PFA, both polyclonal (Fig 1A1) and monoclonal (Fig 1A2) anti-nucleolin Abs labeled THP-1 cell surface, as previously described [12]. When cells were first treated by PFA and then incubated with the different antibodies, only staining of cytoplasm was observed, most likely due to permeabilization of the cell membrane and entry of the antibody into the cytosol (Fig 1A3). Therefore, all subsequent fluorescent experiments were performed, by incubating cells with antibodies before treatment with PFA. We also monitored the changes in cell surface nucleolin expression upon LVS infection by FACS analysis (Fig 1B). Fluorescence intensity of cell surface expressed nucleolin decreased from 5 x 102 +/- 1 x 102 A.U. (arbitrary units) in uninfected cells (Fig 1B1) to 5 x 101 +/- 0.5 x 101 A.U., when cells were infected by LVS (Fig 1B2).
###end p 41
###begin p 42
###xml 0 97 0 97 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Down-regulation of cell surface nucleolin on THP-1 monocyte-like cell surface after LVS infection</bold>
###xml 99 100 99 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 188 195 188 195 <bold xmlns:xlink="http://www.w3.org/1999/xlink">part A1</bold>
###xml 205 212 205 212 <bold xmlns:xlink="http://www.w3.org/1999/xlink">part A2</bold>
###xml 259 266 259 266 <bold xmlns:xlink="http://www.w3.org/1999/xlink">part A3</bold>
###xml 432 435 432 435 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B: </bold>
###xml 510 512 510 512 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B1</bold>
###xml 551 553 551 553 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B2</bold>
###xml 635 646 635 646 <bold xmlns:xlink="http://www.w3.org/1999/xlink">dotted line</bold>
###xml 672 682 672 682 <bold xmlns:xlink="http://www.w3.org/1999/xlink">solid line</bold>
Down-regulation of cell surface nucleolin on THP-1 monocyte-like cell surface after LVS infection. A: THP-1 cells in suspension were incubated first with anti-nucleolin either polyclonal (part A1) or MAb (part A2), diluted 1/200 and then treated with PFA. In part A3, THP-1 cells were first treated by PFA and then incubated with polyclonal anti-nucleolin Ab. Analysis was performed by fluorescence microscopy at 63x magnification. B: FACS analysis of nucleolin expression on cell surface of uninfected cells (B1) or cells infected for 30 min by LVS (B2). THP-1 cells were incubated either with anti-GAPDH as isotype negative control (dotted line) or with anti-nucleolin (solid line) MAbs. These experiments are representative of five different experiments.
###end p 42
###begin title 43
###xml 51 56 <span type="species:ncbi:9606">human</span>
Nucleolin mediates binding of LVS and infection of human monocyte-like THP-1 cells
###end title 43
###begin p 44
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 336 339 336 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e</italic>
###xml 506 507 506 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 67 72 <span type="species:ncbi:9606">human</span>
###xml 386 391 <span type="species:ncbi:9606">human</span>
###xml 428 433 <span type="species:ncbi:9606">human</span>
###xml 493 498 <span type="species:ncbi:9606">human</span>
We evaluated the role of nucleolin in LVS binding and infection of human monocyte-like THP-1 cells, by testing the effect of the pseudopeptide HB-19. This pseudopeptide specifically and irreversibly binds cell-surface expressed nucleolin through its RGG domain located on the C-terminal tail [11,24]. We used THP-1 cells in suspension, i.e. in their monocyte-like state, in presence of human serum AB, as opsonization of LVS by human complement has been shown to enhance its ability to infect human cells [5].
###end p 44
###begin p 45
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 393 394 393 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 395 396 395 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 166 171 <span type="species:ncbi:9606">human</span>
Effect of HB-19 on LVS binding on THP-1 cells was followed using fluorescent microscopy. We counted the number of LVS bacteria expressing GFP (LVS-GFP) bound per 100 human THP-1 cells in fifteen different fields (Fig 2A). The mean number of bacteria bound per cell was almost one bacterium per cell, a value consistent with previous reports on monocytes or macrophage-derived monocytes (MDM) [5,6]. Pre-incubation of THP-1 cells with HB-19 resulted in a 63% decrease in the number of bound LVS-GFP bacteria. We used as a negative control, the protease-resistant basic 9Arg peptide (9R) that does not interact with nucleolin. As expected, this peptide did not significantly affect the number of bacteria bound on THP-1 cells.
###end p 45
###begin p 46
###xml 0 105 0 105 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Interaction of nucleolin with LVS is involved in binding and infection of human monocyte-like THP-1 cells</bold>
###xml 107 108 107 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 687 688 684 685 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1170 1171 1164 1165 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 74 79 <span type="species:ncbi:9606">human</span>
###xml 471 476 <span type="species:ncbi:9606">human</span>
Interaction of nucleolin with LVS is involved in binding and infection of human monocyte-like THP-1 cells. A: THP-1 cells were incubated in RPMI, in absence or in presence of 5 muM HB-19 pseudopeptide or 9R control peptide. Opsonized LVS transformed with GFP expressing plasmid (LVS-GFP) were then added for 30 min. THP-1 cells were analyzed by fluorescence microscopy. Fifteen fields containing average of 100 cells were examined to quantify number of bacteria bound on human cells. Data show mean from three independent experiments +/- SD values indicated as error bars. * = p < 0.01, indicates significant difference for HB-19-treated group compared to control group with 9R peptide. B: Intracellular replication of LVS. THP-1 cells were incubated with RPMI, 5 muM HB-19 or 9R before addition of opsonized LVS for 30 min. Cells were washed with RPMI containing gentamicin to kill extracellular bacteria and incubated in RPMI-FCS and gentamicin for indicated times. Quantification of intracellular bacteria was performed as described in Methods. Results show mean from three independent experiments, each performed in triplicate +/- SD values indicated as error bars. C: THP-1 cells were incubated either with RPMI, 10 muM HB-19 alone or in presence of anti-CR3 Mab, 10 muM 9R or F3, or anti-CR3 Mab. Opsonized LVS were added for 30 min. Cells were washed with RPMI containing gentamicin and incubated in RPMI-FCS and gentamicin for 22 h. Quantification of intracellular bacteria was performed as described in Methods. Results show mean from five independent experiments, each performed in triplicate +/- SD values indicated as error bars.
###end p 46
###begin p 47
###xml 90 92 88 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 162 164 158 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 256 258 251 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 291 293 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 789 794 780 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e. </italic>
###xml 850 852 841 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 1044 1046 1035 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1157 1159 1148 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1208 1210 1199 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
We then analyzed effect of HB-19 treatment on infection by LVS. At 4 h, the 4 +/- 0.5 x 104 CFU/ml obtained in presence of RPMI were decreased to 1.5 +/- 0.2 x 104 CFU/ml in presence of 5 muM HB-19. Maximum of intracellular bacterial multiplication (7 x 106 CFU/ml) was reached at 22 h (Fig 2B), corresponding to average of 11 intracellular bacteria per cell. When THP-1 cells were pre-incubated with 5 muM HB-19, a 63% decrease in LVS infection was observed at 22 h. The strongest inhibitory effect of infection at 22 h was observed with a concentration of 10 muM HB-19 (evaluated over a range of concentration from 1 to 10 muM HB-19, data not shown). Therefore, all following experiments were performed with 10 muM HB-19, with number of intracellular bacteria at 22 h decreased by 78%, (i.e. yielding to average number of 2 bacteria per cell) (Fig 2C). 9R peptide had no significant effect on LVS infection of THP-1 cells. As HB-19 pseudopeptide forms an irreversible complex with surface nucleolin by binding to RGG carboxy-terminal domain [24], we also evaluated effect of F3 peptide that binds acidic domains localized at N-terminal part of nucleolin [25]. F3 had no effect on bacterial infection (Fig. 2C).
###end p 47
###begin p 48
###xml 102 103 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 342 343 342 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
Involvement of CR3 receptors in uptake of LVS though complement component has been largely described [6,31] and prompted us to monitor the possible combined effect of HB-19 and anti-CR3 MAb on the level of bacterial infection of THP-1 cells (Fig 2C). Anti-CR3 alone induced 70% decrease in infection, in agreement with previous observations [7]. Strikingly, incubation of THP-1 cells with both HB-19 and anti-CR3 MAb led to 95% decrease in the level of infection (lowering the number of intracellular bacteria in THP-1 cells from 3 to less than 0.6 bacteria per cell).
###end p 48
###begin p 49
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 214 217 213 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A1</xref>
###xml 237 240 235 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A2</xref>
###xml 368 370 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
We tested whether HB-19 could affect CR3 expression by flow cytometry and E-C3bi rosette formation (Fig 3). FACS analysis with anti-CR3 MAb gave a mean intensity for THP-1 cells preincubated with 10 muM HB-19 (Fig 3A1) or 10 muM 9R (Fig 3A2) of 27.37 and 24.54, respectively (as compared to 6.43 with anti-GAPDH). Rosette formation between E-C3bi and THP-1 cells (Fig 3B) was enumerated by phase-contrast microscopy. When THP-1 cells were preincubated with 10 muM HB-19 or 10 muM 9R, 48% and 51% +/- 5% cells, respectively, were found with attached E-C3bi, as compared to 50% +/- 6% cells with RPMI. When cells were preincubated with 20 mug anti-CR3, only 25% +/- 3% cells formed rosettes with E-C3bi. These results suggested that HB-19 does not affect CR3 activity.
###end p 49
###begin p 50
###xml 0 42 0 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of CR3 is not affected by HB-19</bold>
###xml 44 45 44 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 137 139 136 138 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A1</bold>
###xml 155 157 153 155 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A2</bold>
###xml 231 242 229 240 <bold xmlns:xlink="http://www.w3.org/1999/xlink">dotted line</bold>
###xml 262 272 260 270 <bold xmlns:xlink="http://www.w3.org/1999/xlink">solid line</bold>
###xml 349 350 347 348 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
Expression of CR3 is not affected by HB-19. A. FACS analysis of CR3 expression on surface of THP-1 cells preincubated with 10 muM HB-19 (A1) or 10 muM 9R (A2). THP-1 cells were incubated either with anti-GAPDH as negative control (dotted line) or with anti-CR3 (solid line) MAbs. These experiments are representative of three different experiments. B. Binding of E-C3bi on THP-1 cells preincubated either with RPMI, 10 muM HB-19, 10 muM 9R or 20 mug anti-CR3 was determined by counting 100-200 cells by phase-contrast microscopy. Data show mean from three independent experiments +/- SD values indicated as error bars.
###end p 50
###begin p 51
###xml 260 261 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
Preliminary experiments were also performed either with adherent THP-1 cells, obtained after treatment for 48 h with 200 ng/ml phorbol myristate acetate or with monocyte-derived macrophages (MDM), isolated from peripheral blood mononuclear cells as described [5] A similar inhibitory effect at 10 muM HB-19 of 70% and 65% was recorded for adherent THP-1 cells and MDM, respectively (data not shown).
###end p 51
###begin p 52
###xml 84 89 <span type="species:ncbi:9606">human</span>
Altogether, these results showed that nucleolin is involved in LVS interaction with human monocyte-like THP-1 cells and that LVS binding to nucleolin appears to be mediated through its C-terminal domain, as HB-19 binds RGG domain. The additive inhibitory effect of HB-19 on anti-CR3 further suggested that nucleolin interaction with LVS might be complementary to CR3 - C3 interaction.
###end p 52
###begin title 53
Identification of the bacterial ligands for nucleolin
###end title 53
###begin p 54
###xml 69 83 69 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 69 82 <span type="species:ncbi:263">F. tularensis</span>
###xml 143 149 <span type="species:ncbi:10090">murine</span>
###xml 256 261 <span type="species:ncbi:9606">human</span>
Translation factor EF-Tu has been identified by analysis of the anti-F. tularensis immunoproteome as one of the major LVS antigenic protein in murine infection [32], and as an immunoreactive antigen present in membrane proteins enriched fraction of LVS in human infection [33].
###end p 54
###begin p 55
###xml 282 292 282 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 397 411 397 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 580 587 580 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 1048 1051 1048 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A1</xref>
###xml 1153 1155 1153 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1288 1290 1288 1290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1297 1300 1297 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A2</xref>
###xml 397 410 <span type="species:ncbi:263">F. tularensis</span>
###xml 580 587 <span type="species:ncbi:562">E. coli</span>
###xml 795 799 <span type="species:ncbi:10090">mice</span>
We made the assumption that LVS EF-Tu, possibly present on LVS cell surface, could be a ligand for nucleolin and bind to its C-terminal domain. To test this hypothesis, we first prepared a specific anti-EF-Tu antibody. Sequence of LVS gene encoding EF-Tu (FTL_1751) was obtained by in silico analysis of LVS genome [34]. LVS EF-Tu presents 99.7% amino acid identity with EF-Tu from type A strain, F. tularensis Schu S4 (FTT_0137). Purified recombinant EF-Tu, tagged either with polyhistidine tag (His-EF-Tu) or with glutathione S-transferase protein (GST-EF-Tu), were prepared in E. coli. Both recombinant proteins had expected apparent molecular mass (MW) on SDS-PAGE i.e. 43 kDa for His-EF-Tu and 70 kDa for GST-EF-Tu (data not shown). We prepared polyclonal anti-EF-Tu antibody by immunizing mice with His-EF-Tu recombinant protein. The specificity of anti-EF-Tu Ab was demonstrated, as only one protein, characterized by an apparent Mr of 43 kDa, was recognized by anti-EF-Tu Ab, among all proteins present in a whole bacteria cell lysate (Fig 4A1). After cell fractionation of LVS, EF-Tu was found expectedly in the bacterial cytoplasmic fraction [17], but also in the membrane fraction. In contrast, the cytosolic protein IglA was exclusively localized in the cytoplasmic fraction [20] (Fig 4A2).
###end p 55
###begin p 56
###xml 0 49 0 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Identification of bacterial ligands for nucleolin</bold>
###xml 51 57 51 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Part A</bold>
###xml 272 279 271 278 <bold xmlns:xlink="http://www.w3.org/1999/xlink">part A1</bold>
###xml 314 321 313 320 <bold xmlns:xlink="http://www.w3.org/1999/xlink">part A2</bold>
###xml 324 330 323 329 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Part B</bold>
###xml 743 749 741 747 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Part C</bold>
###xml 889 894 886 891 <bold xmlns:xlink="http://www.w3.org/1999/xlink">lane </bold>
Identification of bacterial ligands for nucleolin. Part A. Samples were prepared as outlined in Experimental Procedures, normalized to 50 mug proteins per lane before separation by SDS-PAGE. Immunoblotting (I.B.) was performed either with anti-EF-Tu Ab diluted 1/100,000 (part A1) or anti-IglA Ab diluted 1/5,000 (part A2). Part B. 500 mug LVS membrane proteins were incubated with different concentrations of biotinylated p63 peptide (p63*). Complexes, formed between bacteria proteins and biotinylated p63 peptide, were isolated by purification using avidin-agarose. Purified proteins were analyzed by SDS-PAGE. Immunoblotting (I.B.) was performed with anti-EF-Tu Ab diluted 1/100,000. Mobility of marker proteins is indicated on left side. Part C. Specific binding of EF-Tu present in LVS membranes with RGG domain of nucleolin. 500 mug LVS membrane proteins were preincubated without (lane -) or with 50 muM unlabeled p63 peptide, before incubation with 5 muM biotinylated p63 peptide (p63*). Complex formed between EF-Tu present in bacteria membrane proteins and biotinylated p63 peptide was analyzed by immunoblotting with anti-EF-Tu Ab diluted 1/100,000. In control, 50 mug LVS membrane proteins were run directly.
###end p 56
###begin p 57
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 844 846 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 993 995 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
We then assessed whether EF-Tu present in LVS membrane fractions bound to p63 RGG carboxy-terminal domain of nucleolin, by a pull-down assay. Solubilized LVS membrane proteins were incubated with increasing amounts of biotinylated p63 peptide. The bacterial protein(s)-biotinylated p63 peptide complexes, recovered after passage through avidin-sepharose columns were probed with anti-EF-Tu antibody (Fig 4B). The 43 kDa EF-Tu was detected in LVS membranes by anti-EF-Tu Ab. Increasing amounts of EF-Tu were recovered with increasing concentrations of biotinylated p63, with maximum recovery obtained at 10 muM peptide concentration. An additional product of 32 kDa compatible with a proteolytic degradation product of the protein was also recovered from bound proteins. Similar truncated fragment has been described for EF-Tu of other species [35]. Specificity of EF-Tu binding to 5 muM biotinylated p63 was confirmed by inhibition of this interaction by 10-molar excess of unlabeled p63 (Fig 4C).
###end p 57
###begin title 58
Interaction of recombinant EF-Tu with C-terminal RGG domain of nucleolin is specific
###end title 58
###begin p 59
###xml 110 111 110 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 459 461 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 767 769 766 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
Specificity of EF-Tu interaction with nucleolin was further confirmed by two reciprocal pull-down assays (Fig 5). The first pull-down assay evaluated capacity of recombinant His-EF-Tu to bind to p63 peptide. Recombinant EF-Tu bound in dose-dependent manner to biotin-labeled p63 peptide (Fig 5A) with maximum binding occurring at 8 muM. Specificity of this binding was demonstrated by its inhibition with a 10 to 20-molar excess of unlabeled p63 peptide (Fig 5B). Effect of HB-19 pseudopeptide and F3 or 9R peptides was also tested on EF-Tu interaction with RGG domain. A 10 to 20-molar excess HB-19 markedly inhibited binding of biotin-labeled p63 peptide to EF-Tu, while a 20-molar excess of F3 or 9R peptides that do not interact with nucleolin had no effect (Fig 5B).
###end p 59
###begin p 60
###xml 0 86 0 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Recombinant EF-Tu specifically interacts with RGG carboxy-terminal domain of nucleolin</bold>
###xml 88 89 88 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 482 489 481 488 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Lane S </bold>
###xml 626 627 624 625 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 763 768 760 765 <bold xmlns:xlink="http://www.w3.org/1999/xlink">lane </bold>
###xml 1175 1176 1165 1166 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 1277 1278 1267 1268 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 1291 1297 1280 1286 <bold xmlns:xlink="http://www.w3.org/1999/xlink">lane 2</bold>
###xml 1313 1319 1302 1308 <bold xmlns:xlink="http://www.w3.org/1999/xlink">lane 3</bold>
###xml 1597 1603 1584 1590 <bold xmlns:xlink="http://www.w3.org/1999/xlink">lane 1</bold>
Recombinant EF-Tu specifically interacts with RGG carboxy-terminal domain of nucleolin. A. P63 peptide, corresponding to RGG domain of nucleolin binds in dose-dependent manner to recombinant EF-Tu. Aliquots containing 1 mug recombinant His-EF-Tu were incubated with different concentrations of biotin-labeled p63 peptide. Complex formed between His-EF-Tu and biotin-labeled p63 peptide was isolated by purification using avidin-agarose. Purified proteins were analyzed by SDS-PAGE. Lane S shows purified preparation of 0.2 mug His-EF-Tu. Presence of EF-Tu was detected by immunoblotting using anti-EF-Tu Ab diluted 1/100,000. B. Specific binding of recombinant EF-Tu with RGG domain of nucleolin. Aliquots containing 1 mug of His-EF-Tu were preincubated without (lane -) or with 40 or 80 muM unlabeled p63 peptide before further incubation with 4 muM biotin-labeled p63 peptide. Biotin-labeled p63 peptide (4 muM) was also preincubated with HB-19 (40 or 80 muM), 80 muM F3 or 80 muM 9Arg (9R) peptides before further incubation with 1 mug His-EF-Tu. Complexes formed between His-EF-Tu and biotin-labeled p63 peptide were isolated and analyzed by immunoblotting as in section A. On left is position of molecular weight protein markers. On right is position of 43 kDa His-EF-Tu. C: 5 mug GST (lane 2) or GST-EF-Tu (lane 3) bound on glutathione-Sepharose beads were incubated with THP-1 solubilized membrane proteins (500 mug). After extensive washes, bound proteins were run on SDS-PAGE with, in control, 50 mug proteins solubilized from THP-1 membranes, run directly without incubation with beads (lane 1). Immunoblotting was performed with anti-nucleolin MAb, diluted 1/10,000. Estimated molecular mass (in kDa) of nucleolin is indicated on left of black line.
###end p 60
###begin p 61
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 390 396 390 396 <bold xmlns:xlink="http://www.w3.org/1999/xlink">lane 3</bold>
###xml 436 442 436 442 <bold xmlns:xlink="http://www.w3.org/1999/xlink">lane 2</bold>
###xml 445 452 445 452 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Lane 1 </bold>
###xml 153 158 <span type="species:ncbi:9606">Human</span>
###xml 312 317 <span type="species:ncbi:9606">human</span>
The second pull-down assay showed that nucleolin, present in solubilized proteins from THP-1 cell membranes, interacted with recombinant EF-Tu (Fig 5C). Human solubilized membrane proteins were incubated with glutathione-sepharose bound GST-EF-Tu or GST as control. A protein doublet at 95 kDa, corresponding to human nucleolin, was detected by anti-nucleolin MAb only in GST-EF-Tu sample (lane 3). Nucleolin was not detected with GST (lane 2). Lane 1 shows the amount of nucleolin detected in 50 mug total membrane proteins. Blotting with polyclonal anti-GST demonstrated that same amounts of GST or GST-EF-Tu were loaded in the gel (data not shown). These results demonstrated that "in vitro" a) recombinant EF-Tu interacts with nucleolin present in THP-1 cell membranes; b) RGG p63 carboxy-terminal domain of nucleolin interacts with EF-Tu either recombinant or present in membranes of LVS.
###end p 61
###begin title 62
EF-Tu is localized on bacterial surface
###end title 62
###begin p 63
###xml 139 140 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 338 339 338 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 452 454 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
###xml 295 301 <span type="species:ncbi:9986">rabbit</span>
###xml 357 363 <span type="species:ncbi:9986">rabbit</span>
###xml 367 372 <span type="species:ncbi:10090">mouse</span>
We then tested the surface exposition of EF-Tu, which was detected in LVS membrane fractions, by fluorescence and electron microscopy (Fig 6). Immunofluorescence analysis (Fig 6A) of intact LVS bacteria gave positive labeling with anti-EF-Tu Ab, as with anti-LVS Ab. No signal was obtained with rabbit anti-nucleolin (see Additional file 1) and either NIS (rabbit or mouse) or anti-nucleolin Mab (data not shown). Immunoelectron microscopy of LVS (Fig 6B) showed positive immunogold staining of surface of intact LVS both with anti-EF-Tu Ab and with control anti-LVS Ab. No staining was found with control NIS. These data strongly suggested that a fraction of EF-Tu is exposed at surface of LVS and may therefore interact with cell-surface associated nucleolin.
###end p 63
###begin p 64
###xml 54 68 54 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 0 81 0 81 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Elongation factor Tu is localized on external side of <italic>F. tularensis </italic>LVS membranes</bold>
###xml 83 89 83 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Part A</bold>
###xml 256 263 256 263 <bold xmlns:xlink="http://www.w3.org/1999/xlink">part A1</bold>
###xml 293 300 293 300 <bold xmlns:xlink="http://www.w3.org/1999/xlink">part A2</bold>
###xml 420 426 420 426 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Part B</bold>
###xml 54 67 <span type="species:ncbi:263">F. tularensis</span>
###xml 170 176 <span type="species:ncbi:9986">rabbit</span>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
###xml 538 544 <span type="species:ncbi:9986">rabbit</span>
###xml 623 629 <span type="species:ncbi:10090">murine</span>
Elongation factor Tu is localized on external side of F. tularensis LVS membranes. Part A. Fluorescence microscopy analysis of LVS pellet incubated either with NIS (from rabbit or from mice), anti-EF-Tu or anti-LVS Abs all diluted 1/10,000. Bright fields (part A1) or fluorescence microscopy (part A2) of 15 fields for each group were observed at 63x magnification. Images are representative of 3 different experiments. Part B. Electron micrographs showing attachment of gold spheres to surface of LVS incubated either with anti-EF-Tu or rabbit anti-LVS Abs and examined by nc-IEM. Control micrograph of LVS incubated with murine NIS shows no beads on bacteria cell surface. Electron microscopy was observed at 20,000x magnification. Size bars equal 500 nm.
###end p 64
###begin title 65
###xml 66 79 <span type="species:ncbi:263">F. tularensis</span>
Co-localization of cell-surface expressed nucleolin with EF-Tu of F. tularensis
###end title 65
###begin p 66
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 439 441 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 537 538 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 676 677 670 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 828 829 822 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 957 971 951 965 <bold xmlns:xlink="http://www.w3.org/1999/xlink">see red arrows</bold>
###xml 1037 1053 1031 1047 <bold xmlns:xlink="http://www.w3.org/1999/xlink">see white arrows</bold>
###xml 1255 1256 1249 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 57 62 <span type="species:ncbi:9606">human</span>
###xml 590 596 <span type="species:ncbi:10090">murine</span>
Localization of EF-Tu at LVS surface and of nucleolin on human cell surface prompted us to investigate by confocal microscopy, whether they could co-localize on THP-1 cell surface (Fig 7). For that purpose, THP-1 cells were first incubated with LVS for 30 min at 37degreesC, before further incubation with polyclonal anti-nucleolin Ab. Under these conditions, anti-nucleolin Ab labels cell surface and not intracellular nucleolin (see Fig 1A). This polyclonal anti-nucleolin Ab was shown not to cross-react with LVS (see Additional file 1). Binding of opsonized bacteria was monitored with murine anti-EF-Tu Ab, which specifically recognized the 43 kDa EF-Tu protein (see Fig 3). Labeling of infected cells with anti-nucleolin Ab gave a lower signal, than when cells are not infected, as already shown by FACS analysis (see Fig 1). Merging of nucleolin with LVS EF-Tu was observed only when EF-Tu present on LVS bacteria met clustered patches of nucleolin (see red arrows). No merging of LVS was observed when nucleolin was not present (see white arrows). To quantify the number of LVS particles co-localizing with nucleolin, we used LVS-GFP particles (see Methods). Merging of LVS-GFP with nucleolin was observed in these conditions (see Additional file 2) and quantified with Imaris program. Regions of interest (ROI) indicated a percentage of 21% +/- 5% LVS-GFP particles co-localizing with nucleolin on more than 500 observed cells.
###end p 66
###begin p 67
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Cell surface nucleolin co-localizes with LVS elongation factor Tu</bold>
###xml 412 423 412 423 <bold xmlns:xlink="http://www.w3.org/1999/xlink">right panel</bold>
###xml 445 455 445 455 <bold xmlns:xlink="http://www.w3.org/1999/xlink">left panel</bold>
###xml 458 469 458 469 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Red arrows </bold>
###xml 540 553 540 553 <bold xmlns:xlink="http://www.w3.org/1999/xlink">White arrows </bold>
###xml 204 209 <span type="species:ncbi:9606">Human</span>
###xml 240 246 <span type="species:ncbi:9986">rabbit</span>
###xml 307 313 <span type="species:ncbi:10090">murine</span>
Cell surface nucleolin co-localizes with LVS elongation factor Tu. THP-1 cells were incubated for 30 min with opsonized LVS and their interaction was observed by confocal microscopy at 63x magnification. Human cell surface was labeled with rabbit anti-nucleolin Ab diluted 1/200. Bacteria were labeled with murine anti-EF-Tu Ab diluted 1/2,000. Merging was observed with 3 x Zoom either with fluorescence light (right panel) or as bright field (left panel). Red arrows indicate colocalization of LVS with nucleolin present on cell surface. White arrows indicate LVS bound on cell surface in absence of nucleolin. These two photos are representative of five different experiments.
###end p 67
###begin title 68
###xml 57 62 <span type="species:ncbi:9606">human</span>
Anti-EF-Tu antibody inhibits binding to and infection of human monocyte-like THP-1 cells by LVS
###end title 68
###begin p 69
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8A</xref>
###xml 854 856 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8B</xref>
###xml 885 887 882 884 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 955 957 950 952 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 1043 1045 1038 1040 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 1571 1573 1566 1568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8C</xref>
###xml 1768 1769 1763 1764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1770 1772 1765 1767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 328 333 <span type="species:ncbi:9606">human</span>
###xml 1357 1362 <span type="species:ncbi:9606">human</span>
###xml 1903 1908 <span type="species:ncbi:9606">human</span>
Involvement of EF-Tu in binding of LVS on THP-1 cells was assessed by fluorescence analysis, using LVS-GFP bacteria and THP-1 cells (Fig 8A). THP-1 cells were therefore incubated with opsonized LVS-GFP bacteria that had been pre-incubated either with RPMI, NIS or anti-EF-Tu Ab. A maximum binding of 95 LVS-GFP bacteria per 100 human cells was recorded, in presence of RPMI or NIS. When surface-exposed EF-Tu was blocked by anti-EF-Tu Ab, number of bacteria bound per 100 cells was decreased by 58%. Consistent with this, soluble recombinant EF-Tu also decreased the number of bacteria bound on cells. Indeed, incubation of THP-1 cells with 50 mug His-EF-Tu before infection with opsonized LVS-GFP decreased LVS binding by 57%. We then analyzed effect of anti-EF-Tu Ab on intracellular replication of LVS after THP-1 cell infection by opsonized LVS (Fig 8B). At 4 h, the 5 +/- 0.6 x 105 CFU/ml obtained in presence of RPMI were decreased to 1 +/- 0.2 x 105 CFU/ml with anti-EF-Tu Ab. Maximum of intracellular bacterial multiplication (6.5 x 106 CFU/ml) was reached between 22 to 30 h after infection. A maximum decrease (60%) in bacterial number was observed at 22 h when bacteria were pre-incubated with anti-EF-Tu Ab. This corresponded to a decrease from 11 to 4 intracellular bacteria per cell. All these experiments were performed in presence of normal human serum. We therefore analyzed at 22 h whether anti-EF-Tu Ab had a similar inhibitory effect on level of infection when LVS was incubated in presence of heat-inactivated (H.I) serum or in absence of serum (Fig 8C). A lower infection of THP-1 cells by LVS was observed, in presence of H.I. serum and in absence of serum (3 and 1.5 intracellular bacteria, respectively), consistent with earlier observations [6,31]. However, even in these conditions, LVS preincubation with anti-EF-Tu Ab resulted in 60% inhibition of infection. Moreover, when human cells were pre-incubated with anti-CR3 MAb and infected by opsonized bacteria that had been pretreated with anti-EF-Tu Ab, maximal decrease of 94% in infection was observed (corresponding to less than 1 bacterium per cell).
###end p 69
###begin p 70
###xml 0 109 0 109 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Elongation factor Tu of LVS participates in binding to human monocyte-like THP-1 cells and in their infection</bold>
###xml 111 112 111 112 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 715 718 712 715 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B: </bold>
###xml 1229 1232 1224 1227 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C: </bold>
###xml 1263 1274 1258 1269 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Human serum</bold>
###xml 1276 1287 1271 1282 <bold xmlns:xlink="http://www.w3.org/1999/xlink">H.I. serum </bold>
###xml 1295 1309 1290 1304 <bold xmlns:xlink="http://www.w3.org/1999/xlink">No Human serum</bold>
###xml 1895 1914 1889 1908 <bold xmlns:xlink="http://www.w3.org/1999/xlink">N.E. (not examined)</bold>
###xml 2002 2012 1996 2006 <bold xmlns:xlink="http://www.w3.org/1999/xlink">H.I serum </bold>
###xml 2016 2031 2010 2025 <bold xmlns:xlink="http://www.w3.org/1999/xlink">No human serum </bold>
###xml 55 60 <span type="species:ncbi:9606">human</span>
###xml 856 861 <span type="species:ncbi:10090">mouse</span>
###xml 1263 1268 <span type="species:ncbi:9606">Human</span>
###xml 1298 1303 <span type="species:ncbi:9606">Human</span>
###xml 1386 1391 <span type="species:ncbi:10090">mouse</span>
###xml 2019 2024 <span type="species:ncbi:9606">human</span>
Elongation factor Tu of LVS participates in binding to human monocyte-like THP-1 cells and in their infection. A: THP-1 cells were infected for 30 min by opsonized LVS-GFP that had been pre-incubated either with RPMI, NIS or anti-EF-Tu Ab (diluted 1/2,000). THP-1 cells were also pre-incubated with 50 mug His-EF-Tu and then infected for 30 min by opsonized LVS-GFP pre-incubated with NIS. Fluorescence microscopy was analyzed at 63x magnification. Fifteen fields containing average of 100 cells were examined to quantify number of bound bacteria. Results shown are means +/- SD from three independent experiments. *, p < 0.01 for group of bacteria treated with anti-EF-Tu Ab compared to group incubated with RPMI. B: Intracellular replication of LVS. THP-1 cells were infected for 30 min with opsonized LVS that were first incubated either with RPMI (), mouse NIS () or anti-EF-Tu Ab (), both diluted 1/2,000. Cells were then washed with RPMI containing gentamicin and further incubated in RPMI-FCS and gentamicin for indicated times. Quantification of intracellular bacteria was performed as described in Methods. Results shown are means from five independent experiments, each in triplicate +/- SD indicated by error bars. C: LVS were incubated either with Human serum, H.I. serum or with No Human serum. LVS in these different conditions were further incubated either with RPMI, mouse NIS or anti-EF-Tu Ab, both diluted 1/2,000. THP-1 cells were then infected by the different LVS preparations. THP-1 cells, pre-incubated with anti-CR3 MAb were infected with opsonized LVS that had been pretreated or not by anti-EF-Tu Ab. THP-1 cells were also preincubated with 50 mug His-EF-Tu before infection by opsonized LVS. Cells were washed in RPMI with gentamicin and incubated in RPMI-FCS and gentamicin for 22 h. Quantification of intracellular bacteria was performed as described in Methods. N.E. (not examined): anti-CR3 MAb, anti-CR3 MAb and anti-EF-Tu Ab and His-EF-Tu samples were not tested in H.I serum and No human serum conditions. Results shown are means from five independent experiments, each in triplicate +/- SD indicated by error bars.
###end p 70
###begin p 71
###xml 361 366 <span type="species:ncbi:9606">human</span>
All these results indicated that, in addition to C3, EF-Tu was important for LVS infection of THP-1 cells through nucleolin. Specific involvement of EF-Tu in LVS infection was also supported, by the 67% decrease in infection observed using 50 mug recombinant EF-Tu. Altogether, our results show that: i) EF-Tu is involved in LVS binding to - and infection of - human THP-1 monocyte-like cells; ii) in spite of requirement for CR3-C3 interaction for LVS infection, nucleolin - EF-Tu interaction is distinct and should be important to consider.
###end p 71
###begin title 72
Discussion
###end title 72
###begin p 73
###xml 50 64 50 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 50 63 <span type="species:ncbi:263">F. tularensis</span>
###xml 69 74 <span type="species:ncbi:9606">human</span>
###xml 253 258 <span type="species:ncbi:9606">human</span>
###xml 437 442 <span type="species:ncbi:9606">human</span>
###xml 622 627 <span type="species:ncbi:9606">human</span>
The receptor-ligand pathways involved in entry of F. tularensis into human monocytes are still not clearly understood. Here, for the first time, we have characterized protein partners of a bacteria-host cell interaction, which permits entry of LVS into human monocyte-like THP-1 cells and their subsequent infection. We showed that elongation factor EF-Tu expressed at bacterial surface interacts with nucleolin, expressed on surface of human monocyte-like THP-1 cells. Blockade of this interaction, either with nucleolin-binding pseudopeptide HB-19 or with anti-EF-Tu Ab, results in inhibition of LVS bacteria binding to human THP-1 cells and subsequent inhibition of bacterial infection.
###end p 73
###begin p 74
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 961 963 961 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 964 966 964 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1047 1049 1047 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 855 860 <span type="species:ncbi:9606">human</span>
Presence of nucleolin at surface of THP-1 monocyte-like cells was demonstrated by fluorescence microscopy and FACS analysis. The fact that nucleolin expression was decreased following LVS infection suggests that nucleolin plays a role in LVS adhesion and does affect entry process and infection. Nucleolin has three main structural domains [9]: 1) N-terminal domain, containing several long stretches of acidic residues; 2) central globular domain, containing four RNA binding domains (RBDs); and 3) C-terminal domain containing nine repeats of tripeptide motif arginine-glycine-glycine (RGG domain = 63 amino acid residues). We demonstrated the important role of nucleolin in LVS infection by using nucleolin-specific peptides. HB-19 pseudopeptide, which specifically binds the RGG C-terminal domain of nucleolin, inhibited both binding and infection of human monocyte-like THP-1 cells infection by LVS. The basic 9R peptide, which does not bind to nucleolin [11,23] or the F3 tumor-homing peptide, which binds on N-terminal domain of nucleolin [25], had no effect on LVS infection. These results confirmed the specific role of nucleolin in LVS infection and demonstrated that nucleolin interacts with LVS through its carboxy-terminal RGG domain.
###end p 74
###begin p 75
###xml 77 79 77 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ca</italic>
###xml 234 235 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
We used THP-1 cells in suspension for our experiments. The limited amount of ca. 90 bacteria bound per 100 THP-1 monocyte-like cells we observed was very similar to that previously found with macrophages and MDM (67-75 Ft/100 cells) [8]. Nevertheless, phagocytic activity of non-adherent THP-1 cells showed to be sufficient to internalize bacteria and promote active intracellular multiplication, since an average of ten bacteria per infected cell was found at 22 h after infection. In preliminary experiments performed either with adherent THP-1 cells, or with MDM, a similar inhibitory effect of HB-19 was recorded with these cells. In view of this result, further investigations are required to evaluate the implication of nucleolin in LVS infection of phagocytic cells other than THP-1 cells.
###end p 75
###begin p 76
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 167 170 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 510 515 <span type="species:ncbi:9606">human</span>
RGG domain of nucleolin constitutes the binding site for various ligands such as subset of ribosomal proteins [12,36,37], midkine, pleiotrophin, lactoferrin, and even HIV particles [23,37-40]. P63 synthetic peptide, which corresponds to RGG domain of nucleolin, allowed us to characterize the bacterial partner of nucleolin, elongation factor Tu. The C-terminal RGG domain bound both intact bacteria and recombinant EF-Tu. Direct interaction of nucleolin with EF-Tu was also demonstrated by co-localization on human cell surface of both proteins and by a pull-down assay where solubilized nucleolin interacted with recombinant GST-EF-Tu.
###end p 76
###begin p 77
###xml 707 719 703 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Francisella </italic>
###xml 821 822 817 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 170 175 <span type="species:ncbi:9606">human</span>
###xml 319 324 <span type="species:ncbi:9606">human</span>
###xml 522 527 <span type="species:ncbi:9606">human</span>
###xml 733 738 <span type="species:ncbi:9606">human</span>
Human nucleolin therefore serves as surface receptor for EF-Tu presented by LVS and this interaction plays a major role in binding of LVS and its subsequent infection of human monocyte-like THP-1 cells. Nucleolin-specific HB-19 pseudopeptide, anti-EF-Tu Ab and recombinant EF-Tu inhibited both binding and infection of human monocyte-like THP-1 cellss. Coating bacteria with anti-EF-Tu Ab did not confer subsequent phagocytosis by Fc receptors as a lower number of CFU was obtained. We always used the same batch of fresh human serum in all experiments to avoid differential effect due to donor-dependent FcgammaR involvement on opsono-phagocytosis. Indeed, presence of a low concentration of antibodies to Francisella in non-immune human serum, which will create ligands for Fc receptors, has been previously described [6].
###end p 77
###begin p 78
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 908 909 908 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 910 912 910 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 834 839 <span type="species:ncbi:9606">human</span>
Fate of surface nucleolin after its interaction with LVS, observed by FACS analysis and its subsequent internalization, remain to be investigated, inasmuch as in all microscopy and flow cytometry experiments, primary Abs were added to living cells at room temperature where pinocytosis still occurs. It has been already suggested that internalization of nucleolin-binding ligands occur via lipid rafts [23,24,37,39]. While surface nucleolin is readily solubilized by treatment of cells with non-ionic detergent, it becomes detergent-resistant after ligand binding to cells and is recovered along detergent insoluble membrane microdomains containing lipid raft. Internalization of LVS through nucleolin was blocked by cytochalasin D (data not shown). This result is consistent with previous data, which showed that infection by LVS of human monocyte-like THP-1 cells was completely blocked by cytochalasin D [5,13].
###end p 78
###begin p 79
###xml 83 97 83 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 351 373 351 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lactobacillus johsonii</italic>
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 589 612 589 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Listeria monocytogenes </italic>
###xml 707 709 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 745 765 745 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Anaplasma marginale </italic>
###xml 832 834 832 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 859 861 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 911 925 911 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. aeruginosa </italic>
###xml 83 96 <span type="species:ncbi:263">F. tularensis</span>
###xml 171 176 <span type="species:ncbi:9606">human</span>
###xml 402 407 <span type="species:ncbi:9606">human</span>
###xml 589 611 <span type="species:ncbi:1639">Listeria monocytogenes</span>
###xml 745 764 <span type="species:ncbi:770">Anaplasma marginale</span>
###xml 911 924 <span type="species:ncbi:287">P. aeruginosa</span>
###xml 960 965 <span type="species:ncbi:9606">human</span>
A fraction of EF-Tu was localized at the LVS surface. This is the first protein of F. tularensis to be characterized as a specific ligand involved in bacterial entry into human monocyte-like THP-1 cells. Interestingly, recent studies have unraveled an unexpected key role for EF-Tu in microbial pathogenesis, e.g. i) EF-Tu, located at cell surface of Lactobacillus johsonii, mediates its attachment to human intestinal cells and mucins [41]; ii) EF-Tu is one of the six most abundant mycobacterial proteins, whose expression increases after phagocytosis by macrophages [42]; iii) EF-Tu of Listeria monocytogenes is target for a serine-threonine phosphatase, which is involved in virulence of this pathogen [35]; iv) EF-Tu is present in purified Anaplasma marginale outer membranes that induce complete protection against infection [43]. A very recent report [44] also demonstrates that bacterial surface Tuf of P. aeruginosa acts as virulence factor and binds human complement factor H and plasminogen.
###end p 79
###begin p 80
###xml 858 860 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1006 1008 1006 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
EF-Tu belongs to the growing list of cytoplasmic proteins identified on bacterial surface. At present, the mechanisms of their surface localization and attachment to the bacterial envelope remain unclear. Indeed, these proteins (including EF-Tu, pyruvate kinase, glyceraldehyde-3-phosphate dehydrogenase and ribosomal proteins) do not contain signal peptides that could direct them into classical secretory pathways and do not possess any obvious envelope-associating motifs. Localization of EF-Tu at the bacterial surface may be explained by its three-dimensional structure. Indeed, EF-Tu protein consists of three domains: an alpha/beta domain (residues 1 to 200), which contains the binding site of the GDP cofactor and two all-beta domains (residues 209 to 299 and 300 to 393), which belong to the tertiary structural class of antiparallel beta-barrels [45]. At this stage, it is tempting to imagine a model somewhat similar to that described in gram-negative bacteria for the autotransporter pathway [46], where the C-terminal part of the precursor forms a porin-like structure within the outer membrane. The N-terminally attached passenger domain is ultimately translocated to the cell surface through this pore. However, in the autotransporter pathway, an N-terminal signal peptide drives the transport of the precursor protein across the inner membrane. Various "environmental" signals might trigger translocation of a subpopulation of cytoplasmic proteins to bacterial membrane surface. Alternatively, conformational changes might allow membrane localization of otherwise cytoplasmic proteins, and provide them alternative or "moonlighting" functions in this compartment.
###end p 80
###begin p 81
###xml 492 494 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
Therefore, our results support a "moonlighting function" for bacterial EF-Tu, already described for its eukaryotic analog, the EF1 elongation factor. Indeed, eukaryotic elongation factors have been shown to be concerned in various important cellular processes or serious diseases, including translational control, signal transduction, cytoskeletal organization, apoptosis, adult atopic dermatitis, oncogenic transformation, nutrition, and nuclear processes such as RNA synthesis and mitosis [47,48].
###end p 81
###begin p 82
###xml 312 325 312 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis</italic>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 312 325 <span type="species:ncbi:263">F. tularensis</span>
###xml 395 403 <span type="species:ncbi:9606">patients</span>
EF-Tu also interacted with nucleolin in presence of inactivated C3 and even in absence of C3. While HB-19 presented an additive inhibitory effect on anti-CR3, it did not interfere with CR3 expression and/or its activity. This suggested a receptor pathway independent of CR3. Therefore, by mediating infection by F. tularensis, EF-Tu - nucleolin interaction may play a role in immuno-compromised patients where C3 deficiencies are associated with higher susceptibility to severe infections [49].
###end p 82
###begin p 83
###xml 568 573 <span type="species:ncbi:9606">human</span>
The quantitative importance of nucleolin as a receptor pathway compared to the CR3/C3 pathway has to be assessed by further experiments. Twenty-one percent +/- 5% opsonized LVS co-localized with nucleolin, as quantified by confocal analysis while 78% bacteria had their binding inhibited by HB-19. This difference may be explained by the difference in sensitivity of the diverse methods and conditions used. Indeed, a similar difference was observed for CR3/C3 interaction. While infection by LVS of THP-1 cells preincubated with anti-CR3 was decreased by 70%, 50% of human THP-1 cells formed rosettes with E-C3bi, with only 50% of these rosettes inhibited by anti-CR3 preincubation of the cells.
###end p 83
###begin title 84
Conclusion
###end title 84
###begin p 85
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 577 590 577 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis</italic>
###xml 780 782 776 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 783 785 779 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 922 936 918 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 940 951 936 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tularensis </italic>
###xml 952 953 948 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 954 955 950 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1242 1256 1238 1252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F. tularensis </italic>
###xml 104 115 <span type="species:ncbi:3702">Arabidopsis</span>
###xml 330 341 <span type="species:ncbi:3702">Arabidopsis</span>
###xml 514 519 <span type="species:ncbi:9606">human</span>
###xml 577 590 <span type="species:ncbi:263">F. tularensis</span>
###xml 905 910 <span type="species:ncbi:9606">human</span>
###xml 922 935 <span type="species:ncbi:263">F. tularensis</span>
###xml 1242 1255 <span type="species:ncbi:263">F. tularensis</span>
EF-Tu has been reported to act as stimulator of proinflammatory response in presence of soluble CD14 in Arabidopsis plants [50,51]. EF-Tu was described as acting as pathogen-associated molecular pattern (PAMP) for innate immune system of both animals and plants. After an initial high affinity binding to its receptor, EF-Tu from Arabidopsis induced elements of signal transmission, including activation of MAPK. By similarity to these recent observations, it is tempting to suggest that interaction of EF-Tu with human nucleolin might be involved in innate immune response to F. tularensis, by triggering transduction signals. Indeed, previous reports on macrophage responses to LVS infection included production of inflammatory cytokines and activation of NF-kappaB activation [52,53]. Since phagosomal escape and intra-cytosolic multiplication of LVS in infected monocytes are very similar to those of human pathogenic F. tularensis ssp tularensis [3,4], the mechanism of entry into monocyte-like cells, involving interaction between EF-Tu and nucleolin, might be similar in the two subspecies. Thus, use of either nucleolin-specific pseudopeptide HB-19 or recombinant EF-Tu, could provide attractive therapeutic approaches for modulating F. tularensis infection.
###end p 85
###begin title 86
Abbreviations
###end title 86
###begin p 87
###xml 160 161 160 161 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 412 417 <span type="species:ncbi:9606">human</span>
CR3: complement receptor type 3; EF-Tu: elongation factor Tu; LVS: live vaccine strain; MOI: Multiplicity of Infection; NIS: non immune serum; HB-19: 5 [Lys (CH2N)Pro-Arg]-template-assembled synthetic peptide; 9R: the 9Arg peptide, nine-D-arginine peptide; F3 peptide: the tumor-homing peptide of 34 amino acid residues; the p63 peptide: the synthetic peptide corresponding to the last 63 amino acid residues of human nucleolin.
###end p 87
###begin title 88
Authors' contributions
###end title 88
###begin p 89
MB designed, carried out experiments and drafted the manuscript. AGH designed, carried out experiments and critically revised the manuscript. KM critically revised the manuscript for important intellectual content. JPB synthesized the different peptides. MD performed the electron microscopy experiments. AC designed experiments and revised critically the manuscript for important intellectual content.
###end p 89
###begin title 90
Supplementary Material
###end title 90
###begin title 91
Additional file 1
###end title 91
###begin p 92
###xml 194 201 194 201 <bold xmlns:xlink="http://www.w3.org/1999/xlink">part A1</bold>
###xml 231 238 231 238 <bold xmlns:xlink="http://www.w3.org/1999/xlink">part A2</bold>
###xml 0 6 <span type="species:ncbi:9986">Rabbit</span>
###xml 118 124 <span type="species:ncbi:9986">rabbit</span>
###xml 137 143 <span type="species:ncbi:9986">rabbit</span>
Rabbit anti-nucleolin Ab does not recognize LVS. Fluorescence microscopy analysis of LVS pellet incubated either with rabbit anti-LVS or rabbit anti-nucleolin Abs and observed as bright fields (part A1) or fluorescence microscopy (part A2).
###end p 92
###begin p 93
Click here for file
###end p 93
###begin title 94
Additional file 2
###end title 94
###begin p 95
###xml 97 107 97 107 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Left panel</bold>
###xml 109 114 109 114 <bold xmlns:xlink="http://www.w3.org/1999/xlink">green</bold>
###xml 275 278 274 277 <bold xmlns:xlink="http://www.w3.org/1999/xlink">red</bold>
###xml 320 324 319 323 <bold xmlns:xlink="http://www.w3.org/1999/xlink">blue</bold>
###xml 327 340 326 339 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Center panel)</bold>
###xml 342 354 341 353 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Right panel </bold>
###xml 373 379 372 378 <bold xmlns:xlink="http://www.w3.org/1999/xlink">yellow</bold>
###xml 382 393 381 392 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Red arrows </bold>
###xml 195 200 <span type="species:ncbi:9606">Human</span>
###xml 270 273 <span type="species:ncbi:10090">GAM</span>
Cell surface nucleolin co-localizes with LVS. Interaction of THP-1 cells with opsonized LVS-GFP (Left panel, green) was observed by confocal microscopy on single optical sections (Z = 0.99 mum). Human cell surface was labeled with anti-nucleolin MAb and Alexa-Fluor 568 GAM (red) and cell nuclei were labeled with DAPI (blue) (Center panel). Right panel is a merged image (yellow). Red arrows indicate co-localization of LVS with nucleolin present on cell surface. Scale bar = 30 mum.
###end p 95
###begin p 96
Click here for file
###end p 96
###begin title 97
Acknowledgements
###end title 97
###begin p 98
###xml 246 251 <span type="species:ncbi:9940">sheep</span>
The authors thank J. Svab and B. Krust for helpful technical assistance, Dr. S. Ezine and Dr. C. Evaristo for help for FACS analysis, M. Gerfa, A. Errachid and N. Goudin for help with confocal experiments, Dr. V. Fremeaux-Bacchi for providing EA sheep erythocytes. This work was supported by INSERM, CNRS, University Paris Descartes and by part of a grant from Sanofi-Aventis France and Bayer Pharma.
###end p 98
###begin article-title 99
Tularemia as a biological weapon: medical and public health management
###end article-title 99
###begin article-title 100
###xml 50 72 <span type="species:ncbi:263">Francisella tularensis</span>
Virulence determinants and protective antigens of Francisella tularensis
###end article-title 100
###begin article-title 101
###xml 64 86 <span type="species:ncbi:263">Francisella tularensis</span>
An attenuated strain of the facultative intracellular bacterium Francisella tularensis can escape the phagosome of monocytic cells
###end article-title 101
###begin article-title 102
###xml 34 56 <span type="species:ncbi:263">Francisella tularensis</span>
###xml 147 152 <span type="species:ncbi:9606">human</span>
Virulent and avirulent strains of Francisella tularensis prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages
###end article-title 102
###begin article-title 103
###xml 0 22 <span type="species:ncbi:263">Francisella tularensis</span>
Francisella tularensis enters macrophages via a novel process involving pseudopod loops
###end article-title 103
###begin article-title 104
###xml 85 107 <span type="species:ncbi:263">Francisella tularensis</span>
###xml 111 116 <span type="species:ncbi:9606">human</span>
Characterization of the receptor-ligand pathways important for entry and survival of Francisella tularensis in human macrophages
###end article-title 104
###begin article-title 105
###xml 26 48 <span type="species:ncbi:263">Francisella tularensis</span>
Uptake of serum-opsonized Francisella tularensis by macrophages can be mediated by class A scavenger receptors
###end article-title 105
###begin article-title 106
###xml 52 74 <span type="species:ncbi:263">Francisella tularensis</span>
Differential infection of mononuclear phagocytes by Francisella tularensis: role of the macrophage mannose receptor
###end article-title 106
###begin article-title 107
Molecular dissection of nucleolin's role in growth and cell proliferation: new insights
###end article-title 107
###begin article-title 108
###xml 95 98 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Identification of V3 loop-binding proteins as potential receptors implicated in the binding of HIV particles to CD4(+) cells
###end article-title 108
###begin article-title 109
###xml 9 12 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The anti-HIV pseudopeptide HB-19 forms a complex with the cell-surface-expressed nucleolin independent of heparan sulfate proteoglycans
###end article-title 109
###begin article-title 110
The cell-surface-expressed nucleolin is associated with the actin cytoskeleton
###end article-title 110
###begin article-title 111
###xml 72 77 <span type="species:ncbi:9606">human</span>
Internalization and phagosome escape required for Francisella to induce human monocyte IL-1{beta} processing and release
###end article-title 111
###begin article-title 112
###xml 50 55 <span type="species:ncbi:9606">human</span>
Activation of the EBV/C3d receptor (CR2, CD21) on human B lymphocyte surface triggers tyrosine phosphorylation of the 95-kDa nucleolin and its interaction with phosphatidylinositol 3 kinase
###end article-title 112
###begin article-title 113
###xml 109 133 <span type="species:ncbi:83334">Escherichia coli O157:H7</span>
Cell surface-localized nucleolin is a eukaryotic receptor for the adhesin intimin-gamma of enterohemorrhagic Escherichia coli O157:H7
###end article-title 113
###begin article-title 114
Intimin types alpha, beta, and gamma bind to nucleolin with equivalent affinity but lower avidity than to the translocated intimin receptor
###end article-title 114
###begin article-title 115
###xml 63 70 <span type="species:ncbi:562">E. coli</span>
Immunocytochemical localization of the elongation factor Tu in E. coli cells
###end article-title 115
###begin article-title 116
###xml 113 135 <span type="species:ncbi:263">Francisella tularensis</span>
###xml 139 143 <span type="species:ncbi:10090">mice</span>
Neutrophils are critical for host defense against primary infection with the facultative intracellular bacterium Francisella tularensis in mice and participate in defense against reinfection
###end article-title 116
###begin article-title 117
Construction and characterization of a highly efficient Francisella shuttle plasmid
###end article-title 117
###begin article-title 118
The Francisella pathogenicity island protein IglA localizes to the bacterial cytoplasm and is needed for intracellular growth
###end article-title 118
###begin article-title 119
Internalization of anti-nucleolin antibody into viable HEp-2 cells
###end article-title 119
###begin article-title 120
###xml 66 71 <span type="species:ncbi:9606">human</span>
Separation of active and inactive forms of the third component of human complement, C3, by fast protein liquid chromatography (FPLC)
###end article-title 120
###begin article-title 121
###xml 9 12 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor
###end article-title 121
###begin article-title 122
###xml 9 12 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The anti-HIV pentameric pseudopeptide HB-19 binds the C-terminal end of nucleolin and prevents anchorage of virus particles in the plasma membrane of target cells
###end article-title 122
###begin article-title 123
Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels
###end article-title 123
###begin article-title 124
###xml 13 18 <span type="species:ncbi:9606">human</span>
###xml 39 60 <span type="species:ncbi:2115">Mycoplasma fermentans</span>
###xml 142 160 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Infection of human B lymphoma cells by Mycoplasma fermentans induces interaction of its elongation factor with the intracytoplasmic domain of Epstein-Barr virus receptor (gp140, EBV/C3dR, CR2, CD21)
###end article-title 124
###begin article-title 125
###xml 27 49 <span type="species:ncbi:263">Francisella tularensis</span>
###xml 64 69 <span type="species:ncbi:9606">human</span>
###xml 74 80 <span type="species:ncbi:10090">murine</span>
###xml 114 119 <span type="species:ncbi:9606">human</span>
The live vaccine strain of Francisella tularensis replicates in human and murine macrophages but induces only the human cells to secrete proinflammatory cytokines
###end article-title 125
###begin article-title 126
###xml 83 86 <span type="species:ncbi:10116">rat</span>
Calcitonin receptor-like receptor and receptor activity modifying protein 1 in the rat dorsal horn: Localization in glutamatergic presynaptic terminals containing opioids and adrenergic [alpha]2C receptors
###end article-title 126
###begin article-title 127
###xml 48 70 <span type="species:ncbi:263">Francisella tularensis</span>
Use of immunoelectron microscopy to demonstrate Francisella tularensis
###end article-title 127
###begin article-title 128
###xml 0 26 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
###xml 36 41 <span type="species:ncbi:9606">human</span>
Mycobacterium tuberculosis-infected human macrophages exhibit enhanced cellular adhesion with increased expression of LFA-1 and ICAM-1 and reduced expression and/or function of complement receptors, Fc{gamma}RII and the mannose receptor
###end article-title 128
###begin article-title 129
###xml 33 55 <span type="species:ncbi:263">Francisella tularensis</span>
###xml 59 64 <span type="species:ncbi:9606">Human</span>
Uptake and Intracellular Fate of Francisella tularensis in Human Macrophages
###end article-title 129
###begin article-title 130
###xml 27 49 <span type="species:ncbi:263">Francisella tularensis</span>
###xml 75 81 <span type="species:ncbi:10090">murine</span>
Proteomic analysis of anti-Francisella tularensis LVS antibody response in murine model of tularemia
###end article-title 130
###begin article-title 131
###xml 86 108 <span type="species:ncbi:263">Francisella tularensis</span>
Identification of immunoreactive antigens in membrane proteins enriched fraction from Francisella tularensis LVS
###end article-title 131
###begin article-title 132
###xml 48 70 <span type="species:ncbi:263">Francisella tularensis</span>
Chromosome rearrangement and diversification of Francisella tularensis revealed by the type B (OSU18) genome sequence
###end article-title 132
###begin article-title 133
###xml 113 135 <span type="species:ncbi:1639">Listeria monocytogenes</span>
Translation elongation factor EF-Tu is a target for Stp, a serine-threonine phosphatase involved in virulence of Listeria monocytogenes
###end article-title 133
###begin article-title 134
The glycine-rich domain of nucleolin has an unusual supersecondary structure responsible for its RNA-helix-destabilizing properties
###end article-title 134
###begin article-title 135
###xml 22 25 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Pleiotrophin inhibits HIV infection by binding the cell surface-expressed nucleolin
###end article-title 135
###begin article-title 136
###xml 13 16 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Anchorage of HIV on permissive cells leads to coaggregation of viral particles with surface nucleolin at membrane raft microdomains
###end article-title 136
###begin article-title 137
Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells
###end article-title 137
###begin article-title 138
###xml 34 37 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Midkine, a cytokine that inhibits HIV infection by binding to the cell surface expressed nucleolin
###end article-title 138
###begin article-title 139
###xml 72 95 <span type="species:ncbi:33959">Lactobacillus johnsonii</span>
###xml 112 117 <span type="species:ncbi:9606">human</span>
Cell surface-associated elongation factor Tu mediates the attachment of Lactobacillus johnsonii NCC533 (La1) to human intestinal cells and mucins
###end article-title 139
###begin article-title 140
Differential expression of mycobacterial proteins following phagocytosis by macrophages
###end article-title 140
###begin article-title 141
###xml 56 75 <span type="species:ncbi:770">Anaplasma marginale</span>
Identification of novel antigenic proteins in a complex Anaplasma marginale outer membrane immunogen by mass spectrometry and genomic mapping
###end article-title 141
###begin article-title 142
###xml 22 27 <span type="species:ncbi:9606">Human</span>
###xml 37 59 <span type="species:ncbi:287">Pseudomonas aeruginosa</span>
Immune Evasion of the Human Pathogen Pseudomonas aeruginosa: Elongation Factor Tuf Is a Factor H and Plasminogen Binding Protein
###end article-title 142
###begin article-title 143
###xml 50 66 <span type="species:ncbi:562">Escherichia coli</span>
Refined structure of elongation factor EF-Tu from Escherichia coli
###end article-title 143
###begin article-title 144
The autodisplay story, from discovery to biotechnical and biomedical applications
###end article-title 144
###begin article-title 145
Moonlighting functions of polypeptide elongation factor 1: from actin bundling to zinc finger protein R1-associated nuclear localization
###end article-title 145
###begin article-title 146
Moonlighting proteins: old proteins learning new tricks
###end article-title 146
###begin article-title 147
The role of complement in inflammation and adaptive immunity
###end article-title 147
###begin article-title 148
###xml 76 87 <span type="species:ncbi:3702">Arabidopsis</span>
The N terminus of bacterial elongation factor Tu elicits innate immunity in Arabidopsis plants
###end article-title 148
###begin article-title 149
Perception of the bacterial PAMP EF-Tu by the receptor EFR restricts Agrobacterium-mediated transformation
###end article-title 149
###begin article-title 150
###xml 125 129 <span type="species:ncbi:10090">mice</span>
Akt/Protein kinase B modulates macrophage inflammatory response to Francisella infection and confers a survival advantage in mice
###end article-title 150
###begin article-title 151
###xml 40 60 <span type="species:ncbi:264">Francisella novicida</span>
Macrophage pro-inflammatory response to Francisella novicida infection is regulated by SHIP
###end article-title 151

